zithromax has been researched along with Hepatitis* in 5 studies
1 trial(s) available for zithromax and Hepatitis
Article | Year |
---|---|
Efficacy and safety of intravenous azithromycin followed by oral azithromycin for the treatment of acute pelvic inflammatory disease and perihepatitis in Japanese women.
Pelvic inflammatory disease (PID) is mainly caused by ascending infection from the vaginal flora including the sexually transmitted organisms, Neisseria gonorrhoeae and Chlamydia trachomatis, and lower genital tract endogenous anaerobes, leading to serious consequences including infertility and ectopic pregnancy. To evaluate the efficacy and safety of azithromycin in the treatment of PID that requires initial intravenous therapy, we conducted a multicenter, unblinded, non-comparative phase 3 trial. Intravenous azithromycin (500 mg, once daily) for 1 or 2 days followed by oral azithromycin (250 mg once daily) to complete a total of 7 days treatment was administered to 60 Japanese women with acute PID. The clinical and bacteriological responses were assessed at the end of treatment, and on Days 15 and 29. The most commonly detected baseline causative pathogens were C. trachomatis (12 strains), Prevotella bivia (10 strains), Streptococcus agalactiae (7 strains), N. gonorrhoeae and Peptostreptococcus anaerobius (6 strains each). The clinical success rate on Day 15 was 94.1% (48/51 subjects including perihepatitis). The clinical efficacy and bacterial eradication rates against C. trachomatis and N. gonorrhoeae (including 2 quinolone-resistant strains) were both 100%. Common treatment-related adverse events were diarrhoea, injection site pain, and nausea. All adverse events were mild or moderate in severity. Azithromycin intravenous-to-oral switch therapy demonstrated excellent clinical and bacteriological effects for PID caused by various etiologic agents including quinolone-resistant strains and strains with low susceptibility to azithromycin at in vitro testing. The therapy was well tolerated in the treatment of PID in Japanese women.. NCT00871494. Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Female; Hepatitis; Humans; Intraabdominal Infections; Japan; Middle Aged; Pelvic Inflammatory Disease | 2014 |
4 other study(ies) available for zithromax and Hepatitis
Article | Year |
---|---|
Right upper quadrant pain in a young woman.
Topics: Abdominal Pain; Amoxicillin-Potassium Clavulanate Combination; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Female; Hepatitis; Humans; Pelvic Inflammatory Disease; Peritonitis; Tomography, X-Ray Computed; Young Adult | 2020 |
Fitz-Hugh-Curtis syndrome.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Female; Hepatitis; Humans; Liver; Pelvic Inflammatory Disease; Peritonitis; Tomography, X-Ray Computed | 2019 |
Fitz-Hugh-Curtis syndrome.
Topics: Abdomen; Adult; Azithromycin; Cephalosporins; Chlamydia Infections; Female; Hepatitis; Humans; Liver; Pelvic Inflammatory Disease; Peritonitis; Young Adult | 2017 |
Fitz-Hugh-Curtis syndrome: abdominal pain in women of 26 years old.
Fitz-Hugh-Curtis syndrome is an inflammation of the liver capsule as a complication of pelvic inflammatory disease, whose etiologic agent is the most common C. trachomatis. The acute phase Fitz-Hugh-Curtis syndrome may present with pain in upper right quadrant abdomen, commonly confused with other diseases of the hepatobiliary and gastrointestinal tract. Definitive diagnosis is now possible for non-invasive techniques such as ultrasound, computed tomography, as well as techniques for the isolation of the germ responsible available in most centers. Topics: Abdominal Pain; Adult; Anti-Bacterial Agents; Azithromycin; Blood Cell Count; Chlamydia Infections; Chlamydia trachomatis; Female; Hepatitis; Hepatitis A; Humans; Pelvic Inflammatory Disease; Peritonitis; Tomography, X-Ray Computed | 2011 |